Save more pets from cancer every day
“I’m sorry, there’s nothing more we can do for your pet.” You don’t want to say it to families with dogs or cats; your pet families definitely don’t want to hear it. Thankfully, the emergence of stereotactic radiation (SRS/SRT) has changed the conversation when it comes to cancer care for pets. Our goal at PetCure Oncology is to work closely with you to offer your clients every available option for managing—and potentially even overcoming—their pet’s cancer.
Our partnerships in each market offer the ability to provide a comprehensive range of treatment modalities. That enables our clinical teams to develop individualized patient care plans with every treatment option at their disposal. Sometimes that involves radiation therapy and sometimes it does not, but it always means the best possible care for your patients. And, with unprecedented precision, SRS/SRT is a treatment modality worth considering in many cases.
Our goal is to support your practice and work as a team to offer your clients and patients the safest, most effective and least disruptive treatment possible—whether that’s SRS or another cancer-fighting option. In some cases, that means a veterinarian will refer the case management entirely to PetCure Oncology. Other times, a veterinarian may choose to do initial diagnostics and post-treatment follow-up care at their practice, referring out only for the treatment itself. Most cases fall somewhere in between. We are here to fill whatever role you need to provide your clients with the best cancer care possible.
If you are a primary care veterinarian, know that our local partnerships offer board-certified expertise in radiation oncology, in addition to a wide range of specialty services, as part of our comprehensive cancer care. If you are a specialist, we want to offer our support as a tertiary care facility, enabling you to provide your clients with every available resource for truly comprehensive cancer care. Either way, our intention is to work with you and supplement your existing cancer care to improve the lives of pets and their families.
We understand that SRS is a new care option in veterinary medicine, and we get a lot of questions about how it can be best utilized by existing practices. Here are some general guidelines for when it is appropriate to refer to a PetCure Oncology center:
- When a diagnosis of cancer has been made, or is strongly suspected, and you want your client to understand all of the available treatment options*
- When the patient has an inoperable tumor or is not a surgical candidate
- When surgery is declined by the family
- When clean margins have not been achieved following surgical resection
- When surgery has been performed in the past and the patient now has a recurrence
- When side effects from traditional radiation outweigh the treatment benefits or deter the client
At each location, we have partnered with one of the region’s leading veterinary specialty practices. This gives you and your pet convenient, one-stop access to the most comprehensive and collaborative cancer care.
and Imaging Center (VRIC)
South Carolina Veterinary Specialists
and Emergency Care (SCVSEC)
Southeast Veterinary Oncology and
Internal Medicine (SEVO-Med)
Lakeshore Veterinary Specialists (LVS)
Arizona Veterinary Oncology (AVO)
Pittsburgh Veterinary Specialty and Emergency Center (PVSEC)
SAGE Centers for Veterinary Specialty
and Emergency Care (SAGE)
Our staff will work with you to obtain your patient’s medical records, and you will remain an integral and informed member of the care team throughout the cancer treatment process.
Once SRS treatment is completed, your patient will return to your practice for all follow-up care unless otherwise requested.
SRS can be used to treat a wide range of cancers in pets, including some previously considered “untreatable” due to their sensitive location within the body. Select cancer type or location of tumor to explore SRS treatment options.
- Nasal/paranasal sinus
- Squamous cell carcinoma
- Basal cell
- Salivary gland
- Ceruminous gland
- Bronchogenic/non-small cell lung
- Transitional cell of bladder/prostate/urethra
- Anal gland
- Neuroendocrine carcinoma
- Thymoma (epithelioid)
- Histiocytic sarcoma
- Peripheral nerve sheath tumor/Schwannoma
- Choroid Plexus papilloma
- Multilobular osteochondroma
- Thymoma (lymphoid)
- Multiple Myeloma
- Mast Cell Tumor
Head and neck
- Oral melanomas
- Squamous cell carcinomas
- Acanthomatous amelioblastomas
- Nasal tumors
- Pituitary tumors
- Soft-tissue sarcomas
- Infiltrative lipomas
- Mast cell tumors
Pelvic canal tumors
- Anal gland adenocarcinomas
- Prostatic tumors